NCT02942095 is a Phase 1 clinical trial of Ixazomib in Solid Tumors, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT02942095?

NCT02942095 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02942095?

Interventions in NCT02942095: Ixazomib, Erlotinib.

What condition does NCT02942095 study?

NCT02942095 studies Solid Tumors.

Is NCT02942095 still recruiting?

NCT02942095 is currently completed. Last updated 18 April 2023.

Last reviewed 2023-04-18 · How we verify

NCT02942095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Ixazomib and Erlotinib in Solid Tumors

Completed Phase 1 Last updated 18 April 2023

What this trial tests

Phase 1 trial testing Ixazomib in Solid Tumors in 9 participants. Completed in 7 December 2022.

Timeline

6 March 2017

Primary endpoint
7 December 2022

7 December 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	6 March 2017
Primary completion	7 December 2022
Estimated completion	7 December 2022
Sites	1 location across United States

Drugs / interventions tested

Ixazomib (IXAZOMIB) — full drug profile →
Erlotinib (erlotinib) — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and commercially available to treat non-small cell lung cancer, but its use in advanced solid cancer is considered investigational. Ixazomib is FDA approved. The study doctor can explain how the study drugs are designed to work. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Tundo GR, Sbardella D, Santoro AM, Coletta A, et al · · 2020 · cited 78× · PMID 32442437 · DOI 10.1016/j.pharmthera.2020.107579
Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.
Begalli F, Bennett J, Capece D, Verzella D, et al · · 2017 · cited 51× · PMID 28829404 · DOI 10.3390/biomedicines5030050
Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.
Yuan Y, Lee JJ, Hilsenbeck SG. · · 2019 · cited 38× · PMID 32923856 · DOI 10.1200/po.19.00032
Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E, Khalighfard S, Amiriani T, Khori V, et al · · 2022 · cited 23× · PMID 36149600 · DOI 10.1007/s13402-022-00715-3
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233
Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.
Van Stiphout CM, Luu AK, Viloria-Petit AM. · · 2022 · cited 13× · PMID 36230467 · DOI 10.3390/cancers14194544
An overview of the BOIN design and its current extensions for novel early-phase oncology trials.
Ananthakrishnan R, Lin R, He C, Chen Y, et al · · 2022 · cited 10× · PMID 35812822 · DOI 10.1016/j.conctc.2022.100943

Verify or expand the search:

Other trials of Ixazomib

Trials testing the same drug.

NCT05722405 — Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma · Phase 4 · recruiting
NCT05183139 — A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide an · Phase 4 · withdrawn
NCT04998786 — A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myel · Phase 2 · active not recruiting
NCT04837131 — A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients · Phase 2 · terminated
NCT03888534 — Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphob · Phase 1 · withdrawn

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02942095 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02942095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing